Regeneron Pharmaceuticals SVP Controller Jason Pitofsky Sells $3.83M of Stock
Jason Pitofsky, SVP Controller, sold 4,062 shares of Regeneron Pharmaceuticals, Inc. at $939.57 to $950.76 a share (average $942.19) in 8 transactions, worth $3.83M in total on Nov 4, 2026. Shares held after the trade: 0 (-100.0%).
Regeneron Pharmaceuticals Insider Huda Y. Zoghbi Sells $7.22M of Stock
Huda Y. Zoghbi sold 7,439 shares of Regeneron Pharmaceuticals, Inc. at $970.42 to $971.06 a share (average $970.46) in 2 transactions, worth $7.22M in total on Nov 3, 2026. Shares held after the trade: 1,703 (-22.7%).
Regeneron Pharmaceuticals Insider George L. Sing Sells $20.4M of Stock
George L. Sing sold 21,129 shares of Regeneron Pharmaceuticals, Inc. at $960.57 to $970.18 a share (average $964.38) in 9 transactions, worth $20.4M in total on Nov 2, 2026. Shares held after the trade: 25,147 (-0.8%).
Regeneron Pharmaceuticals Insider Christine A. Poon Sells $7.59M of Stock
Christine A. Poon sold 7,830 shares of Regeneron Pharmaceuticals, Inc. at $966.74 to $971.31 a share (average $969.09) in 6 transactions, worth $7.59M in total on Nov 2, 2026. Shares held after the trade: 5,219 (-3.7%).
Regeneron Pharmaceuticals EVP General Counsel and Secret Joseph J. Larosa Sells $4.31M of Stock
Joseph J. Larosa, EVP General Counsel and Secret, sold 4,466 shares of Regeneron Pharmaceuticals, Inc. at $965.41 to $966.11 a share (average $965.49) in 2 transactions, worth $4.31M in total on Nov 2, 2026. Shares held after the trade: 38,906 (-1.3%).
Regeneron Pharmaceuticals Insider Kathryn Guarini Sells $360K of Stock
Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals, Inc. at $900.00 a share, worth $360K in total on Oct 30, 2026. Shares held after the trade: 603 (-39.9%).
Regeneron Pharmaceuticals Insider Michael S. Brown Sells $1.69M of Stock
Michael S. Brown sold 1,929 shares of Regeneron Pharmaceuticals, Inc. at $875.00 a share, worth $1.69M in total on Oct 30, 2026. Shares held after the trade: 1,380 (-58.3%).
Regeneron Pharmaceuticals EVP Commercial Marion McCourt Sells $984K of Stock
Marion McCourt, EVP Commercial, sold 1,132 shares of Regeneron Pharmaceuticals, Inc. at $869.43 a share, worth $984K in total on Oct 30, 2026. Shares held after the trade: 10,871 (-9.4%).
Regeneron reported a significant increase in total revenues to $5.12 billion for the third quarter of 2026, driven by strong collaboration revenue and net product sales. Net income for the quarter rose to $1.95 billion, up from $1.46 billion in the prior year period, despite higher research and development expenses.
Regeneron reported third quarter 2026 revenues of $5.1 billion, a 36% increase year-over-year, driven by record sales of Dupixent, EYLEA HD, and Libtayo. The company also announced an expanded collaboration with Sanofi involving a $1.0 billion upfront payment and the FDA approval of Pasatru (garetosmab) for fibrodysplasia ossificans progressiva.
Term
Q3 2026
“This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales. Our pipeline of about 50 product candidates is rapidly advancing. We expect an FDA decision for cemdisiran in generalized myasthenia gravis next month; our Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity continue to advance; and we have generated encouraging early data in MASH, POTS, and ovarian cancer. Finally, we expanded our alliance with Sanofi to include four Regeneron-invented, next-generation, long-acting antibodies designed to build on the success of Dupixent.”
Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer
“We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS. Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.”
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer